Study Does Not Support Intensified Screening of Vulvar or Vaginal Malignancies in IBD


Though inflammatory bowel disease patients are generally at higher risk of HPV-related cancers, this data did not support intensified screening for vulvar or vaginal malignancies in female IBD patients.

Although inflammatory bowel disease (IBD) patients are at higher risk of HPV-related cancers, the data did not support intensified screening for vulvar or vaginal malignancies in female IBD patients, according to a study published in Digestive and Liver Disease.1

However earlier onset cancer was reported, and lymphomas were detected in some patients, which tends to be rare in the genital tract. 

“A high percentage of HPV-related tumors might explain the younger age at diagnosis. HPV is strongly associated with higher rates of vaginal cancer in the general population, and other research suggests that IBD patients are at an increased risk for other cancers including cervical cancer,” investigator Maxine D. Rouvroye, MD, PhD candidate, of Amsterdam UMC, Vrije Universiteit Amsterdam, and Amsterdam Gastroenterology & Metabolism, said in a press release.2 “Unfortunately, our data on HPV status are incomplete, as HPV status was analyzed in very few cases.”

Using the Dutch nationwide network and registry of histopathology and cytopathology from 1991 to 2015, researchers retrieved histopathological data of all IBD patients with a vulvar or vaginal (pre-)cancerous lesion and medical history was retrieved from patient records. Additionally, data from the Central Office for Statistics, the Dutch Comprehensive cancer organization, and the IBDSL cohort were obtained to calculate the standardized and age-adjusted incidence rates.

Overall, 55 patients met the inclusion criteria. A standardized incidence rate of 1.2 (95% CI, 0.8-1.7) for vulvar and vaginal carcinoma among adult females with IBD was calculated, which did not significantly differ from the general population. The use of immunosuppressive therapy did not increase the occurrence of vulvovaginal malignancy, nor did it affect the recurrence rate. However, immunosuppressive drugs ever-users were found to be, on average, 11 years younger at the time of their gynecological diagnosis. 

Within the study cohort, 67% of the women with vulvovaginal cancers had Crohn’s disease, versus 33% with ulcerative colitis. Researchers indicated that one potential contributing factor to this could be the use of immunosuppressive drugs earlier and more frequently in the disease course. Even though in this study immunosuppressive therapy did not appear to be a risk factor, a larger sample size could alter this outcome. 

In an editorial commentary, Vito Annese, MD, from the Valiant Clinic & American Hospital in Dubai, said, “these malignancies are clearly more frequent in Crohn's disease patients, were frequently very advanced at the time of diagnosis, and sometimes atypical. Although the authors did not find evidence for more advanced screening yet, it is cautious to recommend yearly gynecological surveillance starting at 40, especially in patients with Crohn's disease who are under immunosuppressive therapy.”3

The authors indicated that regardless of a general awareness among gastroenterologists of an elevated risk of HPV-related neoplasia in IBD, screening for cervical cancer and HPV-vaccination in female IBD patients remains suboptimal. Further, given that IBD patients in general are at higher risk of developing HPV-related oral cavity malignancies, this highlights the importance of screening for HPV and vaccination against high-risk HPV in females as well as males, especially in IBD. 


1. Rouvroye MD, Jack GJ, Mom CH, et al. Vulvar and vaginal neoplasia in women with inflammatory bowel disease. Digestive and Liver Disease. doi:10.1016/j.dld.2019.10.002.

2. Immunosuppressive therapy for inflammatory bowel disease does not increase women’s risk of vulvar or vaginal cancer [news release]. Oxford. Published March 11, 2020. Accessed March 19, 2020. 

3. Annese V. IBD and malignancies: The gender matters. Digestive and Liver Disease. doi:10.1016/j.dld.2019.10.006.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content